Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: generationbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | Outperform → Market Perform | TD Cowen | |
| 11/8/2022 | $9.00 | Buy | Canaccord Genuity |
| 12/15/2021 | $40.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $50.00 → $27.00 | Buy | Needham |
| 12/14/2021 | Outperform → Mkt Perform | William Blair |
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
S-8 - Generation Bio Co. (0001733294) (Filer)
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
DEFA14A - Generation Bio Co. (0001733294) (Filer)
DEF 14A - Generation Bio Co. (0001733294) (Filer)
10-K - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
SCHEDULE 13G/A - Generation Bio Co. (0001733294) (Subject)
8-K - Generation Bio Co. (0001733294) (Filer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:10 a.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is a biotechnology company working to change what's possible for people living
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results."Our selective, redosable cell-targeted lipid nanoparticle (ctLNP) delivery syste
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is a biotechnology company working to chan
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. "Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is a biotechnology company changing what's possible for peo
Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it
Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseasesCompany reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026 CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics
Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2024 financial results. "There is immense potential for a new class of redosable, selectively targeted in vivo genetic medicines to fulfill the needs of people living with diseases that remain unaddressed by existing treatment options," said Geoff
New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress. The company presented data showing that a single IV dose of its ctLNP delivered mRNA encoding a reporter protein to a majority of circulating T cells in non-human primates (NHPs). In the
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is innovating non-viral genetic medicines
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it
Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. "We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "This quarter, process development and scaling of rapid enzymatic synthesis (RES) for prod
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations. She is currently the Chief Operating Officer of Rubius Therapeutics, where she oversees Corporate Strategy, Communications, Quality, Technical Development and Operations. Prior to joining Rubius, Appelhans held multiple executive-level positions at Novartis, including Global
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. Ron Cooper is a global biopharmaceutical executive who currently serves as president, chief executive officer and board member of Albireo Pharma, Inc., a position he has held since June 2015. He has successfully matured Albireo Pharma, Inc. to a clinical-stage public company on the verge of its first drug approval. Prior to joining Albireo Pharma, Inc., Cooper had a 25-year career at Bristol Myers Squibb, d
TD Cowen downgraded Generation Bio from Outperform to Market Perform
Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00
JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously
Needham reiterated coverage of Generation Bio with a rating of Buy and set a new price target of $27.00 from $50.00 previously
William Blair downgraded Generation Bio from Outperform to Mkt Perform
JMP Securities initiated coverage of Generation Bio with a rating of Mkt Outperform and set a new price target of $40.00
William Blair initiated coverage of Generation Bio with a rating of Outperform and set a new price target of $45.00
Needham & Company LLC initiated coverage of Generation Bio with a rating of Buy and set a new price target of $50.00
William Blair initiated coverage of Generation Bio with a rating of Outperform
William Blair initiated coverage of Generation Bio with a rating of Outperform and set a new price target of $45.00